 "Orchid Pharma gets EIR report from USFDA on inspection closure")
Reacting to the news, shares of the company jumped by 9.91% to settle the day at Rs 64.90.
"Orchid received the Establishment Inspection Report (EIR) from United States Food and Drug Administration (USFDA) based on the successful inspection closure for the formulation manufacturing facility," at Irungattukottai, the company said in a BSE filing.
Also Read
The facility was inspected by the USFDA in the month of May 2015, it added.
Establishment Inspection Report (EIR) is given to a establishment after the completion of the inspection by FDA.
Orchid is present in segments such as anti-infectives, anti-inflammatory, central nervous system, cardio vascular, nutraceuticals and oral as well as sterile products.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%